Thus, loss of KEAP1 expression contributes toward resistance to ICB in melanoma, both in mouse models and patient datasets, and the impact of both KEAP1 loss and NRF2 activation should be further interrogated as larger clinical datasets are generated. This evidence concerns the gene NFE2L2 and melanoma.